The intent of a SPORE award is to create a flexible research program that responds rapidly to new advances in basic science by implementing changes in patient care. This challenge can only be undertaken if its governing body has the ability and authority to continuously monitor research plans and progress and make changes when necessary to ensure that research conducted by the SPORE maintains its translational focus. In addition, this program must be able to draw upon the resources of a large research infrastructure in order to achieve its ambitious goals. The purpose of the Administration, Evaluation and Planning Core is to coordinate the varied components of the DF/HCC GI SPORE necessary to provide oversight and leadership of the scientific, administrative and fiscal aspects of the SPORE. The Administration Core's specific aims are:
Aim 1 : Select projects, monitor research progress, and plan for the future Aim 2: Foster collaborative research within the SPORE and between SPOREs Aim 3: Integrate the GI Cancer SPORE into the structure of the DF/HCC Aim 4: Provide necessary resources and fiscal oversight Aim 5: Promote rapid dissemination of significant research findings and facilitate resource exchange between the DF/HCC SPORE and other institutions.
The purpose of the Administration, Evaluation and Planning Core is to coordinate the varied components of the DF/HCC GI SPORE necessary to provide oversight and leadership of the scientific, administrative and fiscal aspects of the SPORE.
| Cao, Yin; Wu, Kana; Mehta, Raaj et al. (2018) Long-term use of antibiotics and risk of colorectal adenoma. Gut 67:672-678 |
| Barry, Joseph D; Fagny, Maud; Paulson, Joseph N et al. (2018) Histopathological Image QTL Discovery of Immune Infiltration Variants. iScience 5:80-89 |
| Danai, Laura V; Babic, Ana; Rosenthal, Michael H et al. (2018) Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558:600-604 |
| Grasso, Catherine S; Giannakis, Marios; Wells, Daniel K et al. (2018) Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov 8:730-749 |
| Corcoran, Ryan B; André, Thierry; Atreya, Chloe E et al. (2018) Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov 8:428-443 |
| Song, Mingyang; Wu, Kana; Meyerhardt, Jeffrey A et al. (2018) Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol 4:71-79 |
| Babic, A; Schnure, N; Neupane, N P et al. (2018) Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol 9:145 |
| Lopes-Ramos, Camila M; Kuijjer, Marieke L; Ogino, Shuji et al. (2018) Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism. Cancer Res 78:5538-5547 |
| Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230 |
| Patra, Krushna C; Kato, Yasutaka; Mizukami, Yusuke et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20:811-822 |
Showing the most recent 10 out of 590 publications
